Ulcerative colitis
Therapeutic area
Immunology
Rare disease
Yes
- Definition
- An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Ulcerative colitis
- Therapeutic area
- Immunology
- ulcerative colitis
- colitis ulcerative
- ulcerative colitis
- ulcerative colitis (disease)
- left-sided ulcerative colitis
- Severity
- Moderate
- Genetic
- Hereditary
- Inflammatory
- Gastroenterology
- Immunology
- MONDO ID
- MONDO:0005101
- Parent condition
- MONDO:0005292
Related records
Broader conditions (16)
- Colitis
- Colonic disorder
- Digestive system disorder
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Gastroenteritis
- Hereditary disease
- Human disease
- Immune system disorder
- Inflammatory bowel disease
- Inflammatory disease
- Intestinal disorder
- Large intestine disorder
Narrower conditions (2)
- Distal colitis
- Pancolitis
Trials (1,778)
- "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial"
- (CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis
- (CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis
- (CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.
- (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets
- 5-HTP in Patients With IBD in Clinical and Biologic Remission:Effect on Fatigue Scores
- 90Second IBD for the Improvement of Self Efficacy and Quality of Life in Inflammatory Bowel Disease Patients
- A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
- A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis
- A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
- A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma
- A Brief Intervention to Improve Adherence in Teens With Inflammatory Bowel Disease
- A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
- A Clinical Study on The Use of DL-endopeptidase-producing Probiotics as an Adjunctive Therapy for Inflammatory Bowel Disease.
- A Clinical Study to Assess the Effects of KB295 in Patients With Ulcerative Colitis (UC) on Gut Microbiota Structure and Function
- A Clinical Study With Adalimumab Biosimilar
- A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients With Ulcerative Colitis
- A Comparative Evaluation of Different Histopathological Indices of Mucosal Healing in Ulcerative Colitis
- A Comparison of Once a Day Dose Compared to 2 Doses/Day
- A Comprehensive Self-Management Intervention for Individuals With Inflammatory Bowel Disease
Approved drugs (23)
- Adalimumab
- Balsalazide disodium
- Betamethasone acetate
- Betamethasone sodium phosphate
- Budesonide
- Dexamethasone
- Dexamethasone sodium phosphate
- Etrasimod arginine
- Golimumab
- Hydrocortisone
- Infliximab
- Isopropyl alcohol
- Mesalamine
- Methylprednisolone
- Mirikizumab
- Olsalazine sodium
- Ozanimod hydrochloride
- Phytonadione
- Prednisolone
- Prednisone
Drugs in development (157)
- 2'-fucosyllactose Phase 1
- Abatacept Phase 3
- Abrilumab Phase 2
- Aldesleukin Phase 1
- Alicaforsen Phase 2
- Allopurinol Phase 3
- Aminolevulinic acid hydrochloride Phase 1
- Aminosalicylic acid Phase 2
- Amiselimod Phase 2
- Amiselimod hydrochloride Phase 2
- Amoxicillin Phase 2
- Andecaliximab Phase 2
- Andrographolide Phase 3
- Anrukinzumab Phase 2
- Apremilast Phase 2
- Aspirin Phase 3
- Azathioprine Phase 3
- Basiliximab Phase 2
- Berberine chloride Phase 1
- Bertilimumab Phase 2
Other linked drugs (9)
- Balsalazide
- Betadex
- Corticotropin zinc hydroxide
- Leminoprazole
- Mebendazole
- Methylprednisolone sodium succinate
- Olsalazine
- Rutin
- Upadacitinib hemihydrate